Cryogenic infrastructure cost is set less by the price tag of individual tanks than by the profile of the facility: sample volume, regulatory level, access frequency and growth path decide which configuration makes sense. Over 10 to 15 years, liquid nitrogen, staff time, qualification and service dominate the total cost of ownership, alongside the risk of having to rebuild an installation that was sized wrongly.
Anyone planning a cryogenic facility receives quotes quickly, but rarely a straight answer to the real question: which investment fits my organisation, and where is less enough? This article sets out four typical investment profiles: a small IVF clinic, a mid-sized biotech company, a national biobank and a multinational pharmaceutical company. For each one we describe the typical configuration, the lifecycle cost drivers, the growth path and the places where a lighter setup does the job.
The general method behind a lifecycle cost calculation is covered in our article on total cost of ownership for cryogenic systems. Here we apply that logic to real facility types.
Every facility carries the same cost blocks. What differs is their weight.
Datasheet figures for Consarctic® cryogenic tanks show how strongly tank size affects nitrogen cost per sample. Static evaporation is 4.8 l/day for 10,400 cryovials (2 ml) in the BSF220+, 8.3 l/day for 25,900 vials in the BSF420+ and 10.3 l/day for 48,000 vials in the BSF820R+.
Per 1,000 vials that works out at roughly 0.46, 0.32 and 0.21 l/day. A large tank is more than twice as economical per sample as a small one, but only once it is full. A half-empty large tank evaporates as much nitrogen as a full one. That tension between efficiency and oversizing runs through all four profiles.
For a sense of scale, under a stated assumption: at 8.3 l/day static evaporation, a BSF420+ uses around 3,000 litres of LN2 a year before a single lid is opened. At an assumed €0.50 per litre, that is roughly €1,500 per tank per year, or just over €22,000 across 15 years. Your actual price per litre depends on volume, delivery model and region and may be well above or below that figure.
Starting point: a few thousand straws and vials holding oocytes, embryos and sperm, daily access, a small lab team and a high level of clinical and legal responsibility towards patients.
Typical configuration: several aluminium ABV+ Series containers (4 to 150 litres) for daily work, plus stainless-steel ABS+ Series tanks for long-term storage. Add monitoring with alarm forwarding, an empty standby vessel for emergency transfer and an ASR+ dry shipper for moving material between clinics.
Lifecycle cost drivers: nitrogen delivered in supply dewars usually costs more per litre than bulk tanker delivery, and someone has to do the manual filling. The eccentric neck opening on ABV+ and ABS+ containers reduces the evaporation surface and therefore LN2 consumption.
Where less is enough: an automatic nitrogen supply with a phase separator and vacuum-insulated line rarely pays off with only a handful of tanks. Reliable monitoring, a standby vessel and clear filling and emergency procedures matter more.
Growth path: add containers from the same series without changing procedures or canister formats. Plan floor space, ventilation and oxygen monitoring for twice the tank count from day one.
Starting point: cell lines, master and working cell banks, preclinical and early clinical batches. The inventory grows quickly and regulatory expectations rise with each development phase.
Typical configuration: a BIOFREEZE® BV45 controlled-rate freezer for reproducible freezing, one to three BSF+ Series tanks in the BSF220+ or BSF420+ size, matching racks and canisters, and monitoring with an audit trail.
Lifecycle cost drivers: the move into GMP. From that point equipment needs qualification, changes go through change control and every tank swap triggers requalification. Buying equipment early that cannot be brought to GMP standard means paying twice.
Where less is enough: in the research phase not every device needs GMP-grade documentation immediately, and storing clinical batches at a CDMO can be a sensible bridge. Our article on cryogenic infrastructure for biotech start-ups shows how to stage the steps.
Growth path: staying with one tank series and one canister format lets you add capacity without new procedures. A first tank that can be qualified to GMP protects early cell banks and avoids a later migration.
Starting point: hundreds of thousands to millions of samples from population or disease cohorts, storage periods measured in decades and a quality system built on ISO 20387.
Typical configuration: high-capacity BSD+ Series tanks or the BSF820R+ with up to 48,000 cryovials per tank, custom storage towers, an automatic liquid nitrogen supply with phase separator and central monitoring across all storage rooms. The GMP cryogenic storage facility at Uniklinik RWTH Aachen shows what an automatically supplied multi-tank installation looks like in practice: Consarctic® feeds 13 tanks through a 74.9-metre vacuum-insulated line.
Lifecycle cost drivers: liquid nitrogen dominates operating cost, so the low per-sample consumption of large tanks pays off directly, as does a short, well-insulated supply line. Floor space, inventory and sample management, and redundancy in supply and monitoring follow.
Where less is enough: not every sample needs fast access. Rarely requested collections can sit in densely packed tanks while frequently used material lives in a smaller, easier-to-reach area. That cuts lid-open time and nitrogen loss.
Growth path: biobanks grow in stages. Design the supply line, control system and room for the final build-out, then add tanks step by step. Our guide to scaling biobank infrastructure covers the details.
Starting point: several sites, often in different countries, holding GMP cell banks, retention samples and clinical material. FDA and EMA inspections are routine.
Typical configuration: standardised tank and furnishing configurations at every site, BIOFREEZE® SMARTLINE for high-throughput GMP environments, automatic nitrogen supply, monitoring that can be reviewed centrally, ASR+ dry shippers with data loggers for inter-site transport and a service contract with 24/7 emergency support.
Lifecycle cost drivers: qualification, requalification and documentation at every site. Each variation in configuration multiplies the validation effort. Downtime risk adds to this: a failure affects not just samples but supply chains and regulatory timelines.
Where less is enough: not every site needs the full setup. A research site with a few tanks can be filled manually, as long as monitoring and documentation meet the corporate standard.
Growth path: a uniform equipment fleet with one partner for planning, commissioning and service reduces coordination effort. Our comparison of a turnkey cryogenic facility versus individual components weighs up the two routes.
Buying too big because it is cheaper per sample. A large tank only saves nitrogen once it fills up. Until then the facility pays to keep empty space cold.
Buying too small without planning for scalability. If room, ventilation and supply are not designed for expansion, a rebuild follows later, often during live operation and with requalification.
Ignoring the lifecycle. A cheaper tank with higher evaporation or a shorter service life costs more over 15 years than it saved at purchase.
Consarctic® is a market-leading German manufacturer of cryogenic systems for the life sciences: BIOFREEZE® controlled-rate freezers, ABV+, ABS+, BSD+ and BSF+ LN2 storage tanks, ASR+ dry shippers and storage furnishings. Our planning starts not with a product catalogue but with your inventory, your growth plan and your regulatory framework.
The result is a configuration for today and an expansion path for tomorrow. Certified technicians carry out commissioning with IQ/OQ, and manufacturing follows ISO 9001 and EN ISO 13485. Maintenance, optimisation and 24/7 emergency service, 365 days a year, support the installation throughout its life.
It depends on sample count, number of containers and how nitrogen is delivered. The largest running costs are liquid nitrogen and the staff time spent filling. A small clinic is usually well served by ABV+ and ABS+ Series containers, monitoring and a standby vessel. An automatic supply rarely pays off with only a few tanks.
When several large tanks need daily filling, when filling time becomes a real staff cost, or when fill levels must be documented without gaps. That is almost always the case in biobanks and pharmaceutical sites, and usually not in a small IVF clinic.
Design room, ventilation, oxygen monitoring and supply line for the final build-out, but buy tanks step by step as demand materialises. Stick to one tank series and one canister format so new capacity arrives without new procedures and with minimal qualification effort.
Staff time, requalification after changes and the risk of sample loss. None of these appear on a quote, yet together they decide the total cost of ownership over 10 to 15 years.
There is no single right cryogenic infrastructure, only the right one for your profile. An IVF clinic needs dependable small-scale storage, a biotech company a GMP-ready growth path, a biobank low cost per sample and a pharmaceutical group consistency across sites.
Planning a new cryogenic facility or expanding an existing one? Talk to the cryogenics experts at Consarctic about the investment profile that fits your organisation.